Icosavax: Weak Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2

 - Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology; end-to-end drug product investigation underway -

- Data indicate favorable preliminary reactogenicity profile -

- Company remains on track for Phase 1/1b topline, interim data for lead program IVX-121 against respiratory syncytial virus (RSV) in 2Q 2022 -

https://finance.yahoo.com/news/icosavax-announces-topline-interim-phase-120000183.html